New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress
<i>Background and objectives</i>: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fib...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/4/530 |
| _version_ | 1827619555947577344 |
|---|---|
| author | Gianluca Bagnato Egidio Imbalzano Caterina Oriana Aragona Carmelo Ioppolo Pierpaolo Di Micco Daniela La Rosa Francesco Costa Antonio Micari Simona Tomeo Natalia Zirilli Angela Sciacqua Tommaso D’Angelo Irene Cacciola Alessandra Bitto Natasha Irrera Vincenzo Russo William Neal Roberts Sebastiano Gangemi Antonio Giovanni Versace |
| author_facet | Gianluca Bagnato Egidio Imbalzano Caterina Oriana Aragona Carmelo Ioppolo Pierpaolo Di Micco Daniela La Rosa Francesco Costa Antonio Micari Simona Tomeo Natalia Zirilli Angela Sciacqua Tommaso D’Angelo Irene Cacciola Alessandra Bitto Natasha Irrera Vincenzo Russo William Neal Roberts Sebastiano Gangemi Antonio Giovanni Versace |
| author_sort | Gianluca Bagnato |
| collection | DOAJ |
| description | <i>Background and objectives</i>: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fibrillation (AF) according to PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Materials and Methods</i>: 175 COVID-19 patients (25 new-onset AF, 22 other types of AF and 128 no-AF) were included in this single-center, retrospective study; clinical and demographic data, vital signs, electrocardiograms and laboratory results were collected and analyzed. The primary outcome of the study was to evaluate the mortality rate in new-onset AF patients according to IL-6 serum levels and PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Results:</i> The incidence of new-onset AF in the study population was 14.2%. Compared to the no-AF group, new-onset AF patients were older with a positive history of chronic kidney disease and heart failure, had higher IL-6, creatinine and urea serum levels whereas their platelet count was reduced. After PaO<sup>2</sup>/FiO<sup>2</sup> stratification, 5-days mortality rate was higher in new-onset AF patients compared to patients with other types of AF and no-AF patients, and mortality risk increases 5.3 fold compared to no-AF (<i>p</i> = 0.0014) and 4.8 fold compared to other forms of AF (<i>p</i> = 0.03). <i>Conclusions:</i> New-onset AF is common in COVID-19 patients and is associated with increased IL-6 serum levels and early mortality. Further studies are needed to support the use of IL-6 as an early molecular target for COVID-19 patients to reduce their high rate of mortality. |
| first_indexed | 2024-03-09T10:31:43Z |
| format | Article |
| id | doaj.art-0ddb376c1c3b44f09c9f3931a00eeff8 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T10:31:43Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-0ddb376c1c3b44f09c9f3931a00eeff82023-12-01T21:12:45ZengMDPI AGMedicina1010-660X1648-91442022-04-0158453010.3390/medicina58040530New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory DistressGianluca Bagnato0Egidio Imbalzano1Caterina Oriana Aragona2Carmelo Ioppolo3Pierpaolo Di Micco4Daniela La Rosa5Francesco Costa6Antonio Micari7Simona Tomeo8Natalia Zirilli9Angela Sciacqua10Tommaso D’Angelo11Irene Cacciola12Alessandra Bitto13Natasha Irrera14Vincenzo Russo15William Neal Roberts16Sebastiano Gangemi17Antonio Giovanni Versace18Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Medicine, Buonconsiglio Fatebenefratelli Hospital, 80122 Naples, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyBIOMORF Department, University of Messina, 98125 Messina, ItalyBIOMORF Department, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100 Catanzaro, ItalyBIOMORF Department, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Medical Translational Sciences, Division of Cardiology, Monaldi Hospital, University of Campania “Luigi Vanvitelli”, 80131 Naples, ItalyDepartment of Medicine, University of Kentucky, Lexington, KY 40506, USADepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy<i>Background and objectives</i>: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fibrillation (AF) according to PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Materials and Methods</i>: 175 COVID-19 patients (25 new-onset AF, 22 other types of AF and 128 no-AF) were included in this single-center, retrospective study; clinical and demographic data, vital signs, electrocardiograms and laboratory results were collected and analyzed. The primary outcome of the study was to evaluate the mortality rate in new-onset AF patients according to IL-6 serum levels and PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Results:</i> The incidence of new-onset AF in the study population was 14.2%. Compared to the no-AF group, new-onset AF patients were older with a positive history of chronic kidney disease and heart failure, had higher IL-6, creatinine and urea serum levels whereas their platelet count was reduced. After PaO<sup>2</sup>/FiO<sup>2</sup> stratification, 5-days mortality rate was higher in new-onset AF patients compared to patients with other types of AF and no-AF patients, and mortality risk increases 5.3 fold compared to no-AF (<i>p</i> = 0.0014) and 4.8 fold compared to other forms of AF (<i>p</i> = 0.03). <i>Conclusions:</i> New-onset AF is common in COVID-19 patients and is associated with increased IL-6 serum levels and early mortality. Further studies are needed to support the use of IL-6 as an early molecular target for COVID-19 patients to reduce their high rate of mortality.https://www.mdpi.com/1648-9144/58/4/530COVID-19atrial fibrillationmortality riskinterleukin 6 |
| spellingShingle | Gianluca Bagnato Egidio Imbalzano Caterina Oriana Aragona Carmelo Ioppolo Pierpaolo Di Micco Daniela La Rosa Francesco Costa Antonio Micari Simona Tomeo Natalia Zirilli Angela Sciacqua Tommaso D’Angelo Irene Cacciola Alessandra Bitto Natasha Irrera Vincenzo Russo William Neal Roberts Sebastiano Gangemi Antonio Giovanni Versace New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress Medicina COVID-19 atrial fibrillation mortality risk interleukin 6 |
| title | New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress |
| title_full | New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress |
| title_fullStr | New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress |
| title_full_unstemmed | New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress |
| title_short | New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress |
| title_sort | new onset atrial fibrillation and early mortality rate in covid 19 patients association with il 6 serum levels and respiratory distress |
| topic | COVID-19 atrial fibrillation mortality risk interleukin 6 |
| url | https://www.mdpi.com/1648-9144/58/4/530 |
| work_keys_str_mv | AT gianlucabagnato newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT egidioimbalzano newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT caterinaorianaaragona newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT carmeloioppolo newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT pierpaolodimicco newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT danielalarosa newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT francescocosta newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT antoniomicari newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT simonatomeo newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT nataliazirilli newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT angelasciacqua newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT tommasodangelo newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT irenecacciola newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT alessandrabitto newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT natashairrera newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT vincenzorusso newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT williamnealroberts newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT sebastianogangemi newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress AT antoniogiovanniversace newonsetatrialfibrillationandearlymortalityrateincovid19patientsassociationwithil6serumlevelsandrespiratorydistress |